LABT (Lakewood-Amedex Biotherapeutics) Insider Ownership: 8.64 % (As of Jun. 28, 2026)


LABT Lakewood-Amedex Biotherapeutics Inc LABT
8 GF Score
Price $3.55
View Full Analysis

What is Lakewood-Amedex Biotherapeutics Insider Ownership?

Lakewood-Amedex Biotherapeutics LABT +2.33% 8 Insider Ownership is 8.64 % as of Jun. 28, 2026. GuruFocus rates LABT with a GF Score™ of 8/100.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Lakewood-Amedex Biotherapeutics's insider ownership is 8.64%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Lakewood-Amedex Biotherapeutics's Institutional Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Lakewood-Amedex Biotherapeutics's Float Percentage Of Total Shares Outstanding is 34.29%.

Lakewood-Amedex Biotherapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Lakewood-Amedex Biotherapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakewood-Amedex Biotherapeutics Insider Ownership Chart

Lakewood-Amedex Biotherapeutics Historical Data

The historical data trend for Lakewood-Amedex Biotherapeutics can be seen below:

2026-05-31
Insider Ownership 8.64
LABT
8GF Score
Lakewood-Amedex Biotherapeutics Inc LABT
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakewood-Amedex Biotherapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 8.64 % mean?
Lakewood-Amedex Biotherapeutics (LABT) has a Insider Ownership of 8.64 % as of Jun. 28, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Lakewood-Amedex Biotherapeutics and its competitors.
Is Lakewood-Amedex Biotherapeutics' Insider Ownership too high?
Lakewood-Amedex Biotherapeutics' current Insider Ownership is 8.64 %. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' Insider Ownership compare to CURX and PBM?
Lakewood-Amedex Biotherapeutics' Insider Ownership of 8.64 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Lakewood-Amedex Biotherapeutics and its competitors. Lakewood-Amedex Biotherapeutics's current Insider Ownership is 8.64 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current Insider Ownership of 8.64 %. The current Insider Ownership is 8.64 %. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current Insider Ownership is 8.64 % as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lakewood-Amedex Biotherapeutics Business Description

Address 8031 Cooper Creek Blvd, Unit 103, University Park, FL, USA, 34201
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score

Get the complete analysis for LABT

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price